Ranibizumab Versus Dexamethasone Implant in Diabetic Macular Edema

Sponsor
G. d'Annunzio University
Study ID
NCT03385382
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
19 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

  • Dexamethasone intravitreal implant 0.7 mg — DRUG
    Intravitreal Implant of dexamethasone
  • Ranibizumab Injection — DRUG
    Injection of ranibizumab

Study Details

Between December 2016 and June 2017 a total of 40 eyes from 40 diabetic retinopathy patients with diabetic macular edema were recruited at the Ophthalmologic Clinic of University "G. d'Annunzio", Chieti-Pescara, Italy.

Key Dates

First listed
Dec 28, 2017
Start date
Dec 6, 2016
Status verified
Dec 2017
Primary completion
Jun 27, 2017
Completion
Jun 27, 2017

Study Design

Enrollment
40 participants (actual)

Arms

  • Arm: Dexamethasone group
    Patients with diabetic macular edema receiving dexamethasone
  • Arm: ranibizumab
    Patients with diabetic macular edema receiving ranibizumab

Primary Outcome Measure

Central macular thickness [ Time Frame: 6 months ]

Related Studies